Wealthcare Advisory Partners’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $304K | Sell |
3,360
-315
| -9% | -$26.4K | 0.01% | 873 |
|
|
2026
Q1 | $294K | Sell |
3,675
-3,213
| -47% | -$265K | 0.01% | 889 |
|
|
2025
Q4 | $587K | Buy |
6,888
+395
| +6% | +$32.4K | 0.01% | 642 |
|
|
2025
Q3 | $505K | Sell |
6,493
-359
| -5% | -$28.1K | 0.01% | 676 |
|
|
2025
Q2 | $536K | Sell |
6,852
-917
| -12% | -$68.4K | 0.01% | 628 |
|
|
2025
Q1 | $563K | Buy |
7,769
+429
| +6% | +$30.7K | 0.02% | 567 |
|
|
2024
Q4 | $543K | Sell |
7,340
-841
| -10% | -$58.9K | 0.02% | 550 |
|
|
2024
Q3 | $540K | Sell |
8,181
-117
| -1% | -$8.5K | 0.02% | 548 |
|
|
2024
Q2 | $766K | Sell |
8,298
-571
| -6% | -$50.6K | 0.02% | 449 |
|
|
2024
Q1 | $848K | Buy |
8,869
+36
| +0.4% | +$3.02K | 0.03% | 414 |
|
|
2023
Q4 | $674K | Sell |
8,833
-570
| -6% | -$39.7K | 0.03% | 421 |
|
|
2023
Q3 | $651K | Sell |
9,403
-816
| -8% | -$65.6K | 0.03% | 369 |
|
|
2023
Q2 | $964K | Buy |
10,219
+86
| +0.8% | +$7.47K | 0.04% | 295 |
|
|
2023
Q1 | $838K | Sell |
10,133
-217
| -2% | -$17.1K | 0.04% | 324 |
|
|
2022
Q4 | $772K | Buy |
10,350
+1,011
| +11% | +$77.9K | 0.04% | 320 |
|
|
2022
Q3 | $772K | Buy |
9,339
+198
| +2% | +$19.1K | 0.04% | 271 |
|
|
2022
Q2 | $869K | Buy |
9,141
+122
| +1% | +$12.6K | 0.05% | 227 |
|
|
2022
Q1 | $1.06M | Buy |
9,019
+607
| +7% | +$68.1K | 0.06% | 185 |
|
|
2021
Q4 | $1.09M | Buy |
8,412
+2,188
| +35% | +$255K | 0.07% | 184 |
|
|
2021
Q3 | $705K | Buy |
6,224
+407
| +7% | +$46.5K | 0.05% | 254 |
|
|
2021
Q2 | $602K | Buy |
5,817
+238
| +4% | +$22.4K | 0.04% | 281 |
|
|
2021
Q1 | $467K | Buy |
+5,579
| New | +$472K | 0.03% | 303 |
|
|
2020
Q2 | – | Sell |
-18
| Closed | -$1K | – | 636 |
|
|
2020
Q1 | $1K | Hold |
18
| – | – | ﹤0.01% | 1386 |
|
|
2019
Q4 | $1K | Hold |
18
| – | – | ﹤0.01% | 1317 |
|
|
2019
Q3 | $1K | Hold |
18
| – | – | ﹤0.01% | 1282 |
|
|
2019
Q2 | $1K | Hold |
18
| – | – | ﹤0.01% | 1245 |
|
|
2019
Q1 | $1K | Hold |
18
| – | – | ﹤0.01% | 1149 |
|
|
2018
Q4 | $1K | Hold |
18
| – | – | ﹤0.01% | 1135 |
|
|
2018
Q3 | $1K | Hold |
18
| – | – | ﹤0.01% | 1172 |
|
|
2018
Q2 | $1K | Sell |
18
-150
| -89% | -$7K | ﹤0.01% | 1174 |
|
|
2018
Q1 | $8K | Hold |
168
| – | – | ﹤0.01% | 767 |
|
|
2017
Q4 | $6K | Hold |
168
| – | – | ﹤0.01% | 753 |
|
|
2017
Q3 | $6K | Buy |
+168
| New | +$6.41K | ﹤0.01% | 617 |
|
Other funds holding EW
Wealthcare Advisory Partners's EW Position: Q2 2026 in Review
Wealthcare Advisory Partners reduced its Edwards Lifesciences (EW) stake by 8.6% in Q2 2026, selling an estimated $26.4K and leaving 3,360 shares worth $304K. The position accounts for 0.01% of the portfolio, ranked #873.
Wealthcare Advisory Partners first reported a position in EW in Q3 2017 and has held it in 33 quarters since. The position peaked at $1.09M in Q4 2021. 1,333 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Wealthcare Advisory Partners held 3,360 shares of Edwards Lifesciences worth $304K as of Q2 2026.
- Wealthcare Advisory Partners sold 315 Edwards Lifesciences shares in Q2 2026, an estimated $26.4K.
- Edwards Lifesciences made up 0.01% of Wealthcare Advisory Partners's portfolio in Q2 2026, its #873 holding.
- Wealthcare Advisory Partners first reported a position in Edwards Lifesciences in Q3 2017 and has held it in 33 quarters since.
- Wealthcare Advisory Partners's Edwards Lifesciences position peaked at $1.09M in Q4 2021.
- 1,333 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Wealthcare Advisory Partners's 13F filing for Q2 2026, filed 9 Jul 2026.